Return to homepagePandemic Pact

to develop a Covid-19 vaccine candidate that could be produced using the existing influenza virus vaccine manufacturing facilities

Grant number: INV-021239

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020

  • Known Financial Commitments (USD)

    $615,250

  • Funder

    Gates Foundation

  • Research Location

    United States of America

  • Lead Research Institution

    PATH

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Not applicable

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

N/A

6 Publications linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil.

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial.

Differential Severe Acute Respiratory Syndrome Coronavirus 2-Specific Humoral Response in Inactivated Virus-Vaccinated, Convalescent, and Breakthrough-Infected Subjects.

Humoral and cellular immune responses to CoronaVac up to one year after vaccination.

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial.

A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses.